Literature DB >> 34058711

Epidemiology and costs of depressive disorder in Spain: the EPICO study.

Eduard Vieta1, Jordi Alonso2, Víctor Pérez-Sola3, Miquel Roca4, Teresa Hernando5, Antoni Sicras-Mainar6, Aram Sicras-Navarro7, Berta Herrera5, Andrea Gabilondo8.   

Abstract

Depressive Disorders are the most common psychiatric diagnoses in the general population. To estimate the frequency, costs associated with Depressive Disorders in usual clinical practice, and in the whole Spanish population, a longitudinal, retrospective, observational study was carried out using data from the BIG-PAC database®. Study population: all patients aged ≥ 18 years with a diagnosis of a Depressive Disorder in 2015-2017. Prevalence was computed as the proportion of Depressive Disorder cases in the adult general population, and the incidence rate, as the number of new Depressive Disorder cases diagnosed per 1,000 person-years in the population using health services, during 2015-2017. We collected demographic variables, comorbidity, direct health costs, and indirect costs (temporary and permanent disability). Health costs related to Depressive Disorders were estimated according to the annual resource use rate (resource/patient/year). Indirect costs were calculated according to the human capital method. Using the study data and information from the Spanish National Institute of Statistics, we estimated the cost of Depressive Disorders corresponding to the Spanish adult population, including premature mortality. 69,217 Depressive Disorder patients aged ≥ 18 years who met the inclusion/exclusion criteria were studied (mean age: 56.8 years; female: 71.4%). Prevalence of Depressive Disorders in the general population was 4.73% (95% CI: 4.70-4.76%). Annual incidence rates (2015-2017) were 7.12, 7.35 and 8.02 per 1,000 person-years, respectively. Total costs observed in our Depressive Disorder patients were € 223.9 million (corresponding to a mean of € 3,235.3; mean/patient/year), of which, 18.4% were direct health care costs and 81.6%, non-health indirect costs (18% temporary occupational disability, 63.6% permanent disability). Considering also the cost of premature death, the mean cost per patient/year was € 3,402 and the estimated societal costs of Depressive Disorders in Spain were € 6,145 million. The prevalence and incidence of Depressive Disorders are consistent with other series reviewed. Resource use and total costs (especially non-health costs) were high.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depressive disorder; Epidemiology; Health costs; Non-health costs

Mesh:

Year:  2021        PMID: 34058711     DOI: 10.1016/j.euroneuro.2021.04.022

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  4 in total

Review 1.  Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders.

Authors:  Alvaro Morcuende; María Salud García-Gutiérrez; Simone Tambaro; Elena Nieto; Jorge Manzanares; Teresa Femenia
Journal:  Front Psychiatry       Date:  2022-04-15       Impact factor: 5.435

2.  The economic burden of pulmonary arterial hypertension in Spain.

Authors:  Néboa Zozaya; Fernando Abdalla; Ignacio Casado Moreno; Carlos Crespo-Diz; Ana M Ramírez Gallardo; Joaquín Rueda Soriano; Macarena Alcalá Galán; Álvaro Hidalgo-Vega
Journal:  BMC Pulm Med       Date:  2022-03-26       Impact factor: 3.317

3.  A Cross-Sectional Study on the Associations between Physical Activity Level, Depression, and Anxiety in Smokers and Ex-Smokers.

Authors:  Ángel Denche-Zamorano; David Manuel Mendoza-Muñoz; Raquel Pastor-Cisneros; José Carmelo Adsuar; Jorge Carlos-Vivas; Juan Manuel Franco-García; Jorge Pérez-Gómez; María Mendoza-Muñoz
Journal:  Healthcare (Basel)       Date:  2022-07-27

Review 4.  The relationship between the Mediterranean diet and Axis I disorders: A systematic review of observational studies.

Authors:  Samaneh Madani; Afsane Ahmadi; Firoozeh Shoaei-Jouneghani; Mahsa Moazen; Najmeh Sasani
Journal:  Food Sci Nutr       Date:  2022-06-06       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.